The ALXN2040-GA-201 Study
A phase 2, double-masked, placebo-controlled, does range finding study of Danicopan (ALXN2040) in patients with geographic atrophy secondary to Age-Related Macular Degeneration.
This study intends to identify the most effective and well-tolerated dosage of Danicopan, an oral medication. Geographic atrophy, a severe form of Age-Related Macular Degeneration characterized by the progressive loss of retinal cells, has limited treatment options. Danicopan, as a complement factor D inhibitor, can be a potential treatment for patients with Geographic Atrophy. The duration of this study is 26 months.